SCHOLAR ROCK HOLDING CORPORATION Basic Shares Outstanding (Weighted Average)
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Basic Shares Outstanding (Weighted Average) of 130.61 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 130.61M shares, a 15.89% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 127.28M shares, a 13.80% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 120.51M shares, a 9.97% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 113.73M shares, a 17.19% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for fiscal 2025 was 114.70M shares, a 14.89% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for fiscal 2024 was 99.84M shares, a 19.79% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for fiscal 2023 was 83.35M shares, a 39.82% increase from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION weighted average number of shares outstanding, basic for fiscal 2022 was 59.61M shares, a 62.38% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 130.61M shares 10-Q · filed 2026-08-06 | 128.95M shares 10-Q · filed 2026-08-06 | 126.13M shares derived: average of 3 quarters · filed 2026-08-06 | 123.03M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 127.28M shares 10-Q · filed 2026-05-07 | 123.89M shares derived: average of 2 quarters · filed 2026-05-07 | 120.51M shares derived: average of 3 quarters · filed 2026-05-07 | 118.56M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 120.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 117.12M shares derived: average of 2 quarters · filed 2026-03-03 | 115.65M shares derived: average of 3 quarters · filed 2026-08-06 | 114.70M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 113.73M shares 10-Q · filed 2025-11-14 | 113.22M shares derived: average of 2 quarters · filed 2026-08-06 | 112.76M shares 10-Q · filed 2025-11-14 | 111.97M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 112.70M shares 10-Q · filed 2026-08-06 | 112.27M shares 10-Q · filed 2026-08-06 | 111.38M shares derived: average of 3 quarters · filed 2026-08-06 | 107.80M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 111.84M shares 10-Q · filed 2026-05-07 | 110.71M shares derived: average of 2 quarters · filed 2026-05-07 | 106.16M shares derived: average of 3 quarters · filed 2026-05-07 | 103.82M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 109.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 103.32M shares derived: average of 2 quarters · filed 2026-03-03 | 101.15M shares derived: average of 3 quarters · filed 2026-03-03 | 99.84M shares 10-K · filed 2026-03-03 |
| 2024-09-30 | 97.05M shares 10-Q · filed 2025-11-14 | 96.93M shares derived: average of 2 quarters · filed 2025-11-14 | 96.59M shares 10-Q · filed 2025-11-14 | 95.70M shares derived: average of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | 96.81M shares 10-Q · filed 2025-08-06 | 96.35M shares 10-Q · filed 2025-08-06 | 95.25M shares derived: average of 3 quarters · filed 2025-08-06 | 91.59M shares derived: average of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | 95.89M shares 10-Q · filed 2025-05-14 | 94.47M shares derived: average of 2 quarters · filed 2025-05-14 | 89.85M shares derived: average of 3 quarters · filed 2025-05-14 | 87.41M shares derived: average of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 93.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 86.82M shares derived: average of 2 quarters · filed 2025-02-27 | 84.59M shares derived: average of 3 quarters · filed 2025-02-27 | 83.35M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 80.61M shares 10-Q · filed 2024-11-12 | 80.36M shares derived: average of 2 quarters · filed 2024-11-12 | 80.12M shares 10-Q · filed 2024-11-12 | 79.98M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 80.12M shares 10-Q · filed 2024-08-08 | 79.87M shares 10-Q · filed 2024-08-08 | 79.77M shares derived: average of 3 quarters · filed 2024-08-08 | 79.66M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 79.61M shares 10-Q · filed 2024-05-07 | 79.59M shares derived: average of 2 quarters · filed 2024-05-07 | 79.51M shares derived: average of 3 quarters · filed 2024-05-07 | 70.03M shares derived: average of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 79.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 79.45M shares derived: average of 2 quarters · filed 2024-03-19 | 66.84M shares derived: average of 3 quarters · filed 2024-03-19 | 59.61M shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 79.34M shares 10-Q · filed 2023-11-07 | 60.48M shares derived: average of 2 quarters · filed 2023-11-07 | 52.96M shares 10-Q · filed 2023-11-07 | 48.90M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 41.62M shares 10-Q · filed 2023-08-09 | 39.55M shares 10-Q · filed 2023-08-09 | 38.76M shares derived: average of 3 quarters · filed 2023-08-09 | 38.24M shares derived: average of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | 37.46M shares 10-Q · filed 2023-05-09 | 37.33M shares derived: average of 2 quarters · filed 2023-05-09 | 37.11M shares derived: average of 3 quarters · filed 2023-05-09 | 36.98M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 37.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | 36.94M shares derived: average of 2 quarters · filed 2023-03-07 | 36.82M shares derived: average of 3 quarters · filed 2023-03-07 | 36.71M shares 10-K · filed 2023-03-07 |
| 2021-09-30 | 36.68M shares 10-Q · filed 2022-11-14 | 36.63M shares derived: average of 2 quarters · filed 2022-11-14 | 36.55M shares 10-Q · filed 2022-11-14 | 35.90M shares derived: average of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | 36.58M shares 10-Q · filed 2022-08-08 | 36.48M shares 10-Q · filed 2022-08-08 | 35.63M shares derived: average of 3 quarters · filed 2022-08-08 | 34.17M shares derived: average of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | 36.38M shares 10-Q · filed 2022-05-16 | 35.16M shares derived: average of 2 quarters · filed 2022-05-16 | 33.37M shares derived: average of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | 33.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | 31.86M shares derived: average of 2 quarters · filed 2022-03-07 | 30.73M shares 10-K · filed 2022-03-07 | |
| 2020-09-30 | 29.78M shares 10-Q · filed 2021-11-09 | 29.67M shares 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |